8 citations
,
August 2018 in “BMJ Case Reports” This case report describes a patient who experienced rapid hair depigmentation after starting pazopanib for metastatic renal cell carcinoma, which may suggest therapy success despite being distressing.
42 citations
,
April 2012 in “Seminars in Oncology” This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.
7 citations
,
August 2022 in “Experimental dermatology” This review discusses the role of YAP/TAZ proteins in skin cancer physiology and tumorigenesis, and the potential of targeting these proteins in skin cancer treatments, but presents no new experimental findings.
16 citations
,
December 2012 in “Bioinformation” This study suggests that natural molecules like curcumin, EGCG, barringtozenol, and finasteride may be effective inhibitors for VEGFR, potentially offering a cancer chemoprevention alternative to pazopanib.
11 citations
,
November 2021 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” This guideline reviews the diagnosis and treatment of malignant cutaneous angiosarcomas, highlighting the complexity of treatment and the importance of early detection despite non-specific clinical presentations.